In the last trading session, 1.95 million shares of the Unity Biotechnology Inc (NASDAQ:UBX) were traded, and its beta was 1.08. Most recently the company’s share price was $1.30, and it changed around -$0.53 or -28.77% from the last close, which brings the market valuation of the company to $21.93M. UBX currently trades at a discount to its 52-week high of $3.10, offering almost -138.46% off that amount. The share price’s 52-week low was $0.94, which indicates that the current value has risen by an impressive 27.69% since then. We note from Unity Biotechnology Inc’s average daily trading volume that its 10-day average is 0.28 million shares, with the 3-month average coming to 246.12K.

Unity Biotechnology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended UBX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Unity Biotechnology Inc is expected to report earnings per share of -0.4 for the current quarter.

Unity Biotechnology Inc (NASDAQ:UBX) trade information

Instantly UBX has showed a red trend with a performance of -28.77% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.8500 on recent trading dayincreased the stock’s daily price by 29.73%. The company’s shares are currently up 33.14% year-to-date, but still down -25.71% over the last five days. On the other hand, Unity Biotechnology Inc (NASDAQ:UBX) is -32.99% down in the 30-day period. We can see from the shorts that 0.55 million shares have been sold at a short interest cover period of 3.47 day(s).

Unity Biotechnology Inc (UBX) estimates and forecasts

Forecasts for the next quarter put sales growth at 0.00%. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 39.36%. Unity Biotechnology Inc earnings are expected to increase by 27.87% in 2025, but the outlook is positive 31.80% per year for the next five years.

Unity Biotechnology Inc (NASDAQ:UBX)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.31% of Unity Biotechnology Inc shares, and 19.58% of them are in the hands of institutional investors. The stock currently has a share float of 19.84%.